Question 1

What are the potential side effects of SI-B001?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors clinical trial (NCT04603287). Contact the study team or your healthcare provider for specific answers.

Question 2

How does SI-B001 compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors clinical trial (NCT04603287). Contact the study team or your healthcare provider for specific answers.

Question 3

What is the expected duration of my participation in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors clinical trial (NCT04603287). Contact the study team or your healthcare provider for specific answers.

Question 4

What kind of monitoring will I receive during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors clinical trial (NCT04603287). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any specific eligibility criteria I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors clinical trial (NCT04603287). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors clinical trial (NCT04603287). Contact the study team or your healthcare provider for specific answers.

What this study is about